- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- BMS-955176, EFV, TDF/FTC
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Los Angeles, California • DeLand, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–27
of 27
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Immune Reconstitution Inflammatory Syndrome, HIV, HIV Infections
- Interventions
- maraviroc, Placebo
- Drug
- Lead sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 4
- States / cities
- Bethesda, Maryland • Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate, Lamivudine and Zidovudine, Lamivudine/Zidovudine, Abacavir sulfate, Efavirenz
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Manhasset, New York + 2 more